Pace Life Sciences, a division of Pace, a Science and Technology Company, announced on November 12, 2026, that it has joined a consortium led by Centillion Biosciences, Inc., selected by the Advanced Research Projects Agency for Health (ARPA-H) under its Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program.

Consortium Work

The consortium will work to address the high cost of manufacturing medications for people living with rare and ultra-rare genetic diseases and to improve accessibility for those who need them.

According to the announcement, traditional drug manufacturing models are not built for personalized genetic medicine. Today's RNA drug manufacturing focuses on large-scale production, typically thousands or more doses, which the company describes as labor-intensive, costly, and not conducive to personalized medicines.

The GIVE initiative is focused on developing manufacturing approaches designed around small patient populations, advancing automated, distributed manufacturing systems capable of producing RNA-based medicines with integrated quality control.

An Integrated Platform for Small Patient Populations

The project will build on Centillion's GMP-qualified Biofoundry-in-a-Box (BiaB) platform and patented continuous-flow technologies to create an integrated manufacturing system.

The platform is intended to take a therapy from DNA input through RNA production and fill-finish, while incorporating quality testing directly into the process. It is designed to support a distributed manufacturing model in which systems could be deployed closer to the patients who need these medicines.

The long-term vision of the GIVE program is a distributed manufacturing network capable of producing individualized RNA medicines at or near the point of care.

For instances where medicine may be needed for only a handful of individuals, the company stated that these innovations could mean the difference between a therapy that exists on paper and one that reaches patients.

Pace's Role from Design Through Manufacturing

Pace Life Sciences is involved with designing and developing the integrated manufacturing platform through the build and proof-of-concept testing. These contributions will continue in later phases, as the platform is expected to be installed at Pace Life Sciences laboratories to support production.

The company stated that real-world drug products by Dana-Farber Cancer Institute, Boston Children's Hospital, Miltenyi Biotec, HDT Bio, and Violet Pharmaceuticals represent different RNA molecules, lipid nanoparticle formulations and disease applications.

Peter Abbink, Ph.D., Boston Site Head at Pace Life Sciences, said that today's drug manufacturing process leads to long timelines and high costs for personalized medicines.

"Putting manufacturing and quality into one integrated system that can produce a clinical drug product for a very small patient population becomes something we can realistically do, not just imagine," he said.

Andy Fenny, President of Pace Life Sciences, said the company is proud to be part of the initiative alongside organizations working to advance individualized genetic medicines.

"For these therapies to become more accessible, manufacturing must evolve beyond traditional large-scale models. Pace® brings the scientific, manufacturing and quality expertise to help translate that vision into a practical platform designed for smaller patient populations," he said.

Origins of the Consortium

Pace's involvement began ahead of the award announcement through an ARPA-H partnering event that brought together industry and academic organizations to address the technical and manufacturing challenges of individualized genetic medicines.

The resulting Centillion-led consortium brings together expertise across genetic medicine development, engineering, manufacturing, analytical science, automation, and quality.

Participants include Pace Life Sciences, Dana-Farber Cancer Institute, Harvard Medical School, Boston Children's Hospital, Triple Ring Technologies, Legomics, Molariti, HDT Bio, p-Chip and other specialist collaborators.

Abbink and Centillion founder Harris Makatsoris recently discussed the program and the future of RNA manufacturing during an episode of The Biotech Voyager hosted by Benjamin McLeod, according to the announcement.

About Pace Life Sciences

Pace Life Sciences delivers scientific certainty to pharmaceutical and biopharmaceutical clients developing therapies, with services spanning early R&D and clinical trial materials production to analytical testing and commercial-stage support.

Across its network of U.S.-based facilities, the company provides regulatory, quality, and laboratory operations support. Pace® is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners.

From Coast to Coast: Monitor Every Significant Pharmaceutical Manufacturing Project Across the US

How many billion-dollar Pharmaceutical Manufacturing projects launched in the United States last quarter without ever coming to your attention? For business development teams, suppliers, and contractors in the chemical sector, missed visibility translates to missed revenue.

The Global Project Tracking (GPT) platform by Blackridge Research provides real-time insights specifically tailored for the pharmaceutical manufacturing sector, tracking capital projects across the United States. Rather than aggregating data from various fragmented sources, you gain access to a cohesive, organized pipeline of opportunities primed for engagement.

Whether you're focusing on emerging chemical projects to stay ahead of competitors or tracking ongoing construction to effectively position your products and services, the platform provides your team with the essential project intelligence required for precise outreach planning.

• Upcoming Projects

• Tender Notices

• Contract Awards

• Projects Under Construction

• Completed Projects

Ready to explore the complete US Pharmaceutical Manufacturing project landscape at a glance? Schedule a Free Demo of the Global Project Tracking (GPT) platform by Blackridge Research today.